欧洲神经生物标志物市场预测至 2027 年 - COVID-19 影响和按产品进行区域分析(蛋白质组学生物标志物、基因组学生物标志物、代谢组学生物标志物、成像生物标志物等);应用(阿尔茨海默病、帕金森病、精神分裂症、亨廷顿病、脊髓性肌萎缩症等);最终用户(制药和生物技术公司、临床诊断、研究组织)

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027


No. of Pages: 144    |    Report Code: TIPRE00013302    |    Category: Life Sciences

Europe Neurological Biomarkers Market

市场介绍

生物标志物是疾病特异性指标。生物技术的进步使得能够测量导致各种神经系统疾病的特定生物标志物,这在以前是不可能的。这些生物标记物的日益普及有助于神经系统疾病的早期检测、微创诊断和更快的药物开发。

市场概况和动态

< /p>

欧洲神经生物标志物市场预计将从 2019 年的 12.2115 亿美元增至 2027 年的 30.6294 亿美元。预计 2020-2027 年该市场的复合年增长率为 12.4%。由于神经系统疾病患病率上升和神经生物标志物研究进展等驱动因素,预计该市场将出现大幅增长。然而,与使用神经生物标志物相关的并发症预计将阻碍市场增长。

关键市场细分

从产品来看,2019年,基因组生物标志物领域占据了最大的市场份额,预计在预测期内将以最快的复合年增长率增长。由于消费者对基因药物益处的认识不断提高以及神经生物标志物领域的技术进步,这一领域可能会出现利润丰厚的增长。此外,采用基因咨询和基因分析进行诊断的趋势转变也可能会促进该领域的增长。遗传生物标志物是重要的模式,可指导更加个性化的倾向和医学分析方法。

主要来源和上市公司

< p>报告中包含的神经生物标志物市场的一些主要主要和次要来源包括世界卫生组织 (WHO)、国家卫生服务体系 (NHS) 、神经科学生物标志物研究和成像 (BRAIN)、欧盟委员会 (EC) 等

购买该报告的理由

  • 了解神经生物标志物市场格局并确定最有可能保证丰厚回报的细分市场
  • 了解神经生物标志物市场不断变化的竞争格局,保持领先地位
  • 有效规划并购和合作交易通过识别最有前景的细分市场来预测神经生物标志物市场
  • 通过对神经生物标志物市场各个细分市场的市场表现进行敏锐和全面的分析,帮助做出明智的业务决策
  • span>
  • 获取欧洲地区 2019 年至 2027 年各细分市场的市场收入预测。

北美神经科生物标记物市场细分

按产品

  • 蛋白质组学生物标记物
  • 基因组学生物标记物
  • 代谢组学生物标志物
  • 成像生物标志物
  • 其他

按应用

  • 阿尔茨海默病
  • 帕金森病
  • 精神分裂症
  • 亨廷顿病
  • 脊髓性肌肉萎缩症
  • 其他
  • 其他
  • li>

最终用户

  • 制药和生物技术公司
  • 临床诊断
  • 研究组织

按地理位置

•             欧洲

  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 公司简介

    • Thermo Fisher Scientific, Inc
    • Myriad Genetics
    • QIAGEN
    • 雅培
    • 默克公司

     



    Europe Neurological Biomarkers Strategic Insights

    Strategic insights for Europe Neurological Biomarkers involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

    strategic-framework/europe-neurological-biomarkers-market-strategic-framework.webp
    Get more information on this report

    Europe Neurological Biomarkers Report Scope

    Report Attribute Details
    Market size in 2019 US$ 1,221.15 Million
    Market Size by 2027 US$ 3,062.94 Million
    Global CAGR (2020 - 2027) 12.4%
    Historical Data 2017-2018
    Forecast period 2020-2027
    Segments Covered By 产品
    • 蛋白质组学生物标志物
    • 基因组学生物标志物
    • 代谢组学生物标志物
    • 成像生物标志物
    By 应用
    • 阿尔茨海默病
    • 帕金森病
    • 精神分裂症
    • 亨廷顿病
    • 脊髓性肌萎缩症
    By 最终用户
    • 制药和生物技术公司
    • 临床诊断
    • 研究组织
    Regions and Countries Covered 欧洲
    • 英国
    • 德国
    • 法国
    • 俄罗斯
    • 意大利
    • 欧洲其他地区
    Market leaders and key company profiles
  • Thermo Fisher Scientific, Inc
  • Myriad Genetics
  • QIAGEN
  • Abbott
  • Merck KGaA
  • Get more information on this report

    Europe Neurological Biomarkers Regional Insights

    The regional scope of Europe Neurological Biomarkers refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-neurological-biomarkers-market-geography.webp
    Get more information on this report

The List of Companies - Europe Neurological Biomarkers Market

  1. Thermo Fisher Scientific, Inc
  2. Myriad Genetics
  3. QIAGEN
  4. Abbott
  5. Merck KGaA
Frequently Asked Questions
How big is the Europe Neurological Biomarkers Market?

The Europe Neurological Biomarkers Market is valued at US$ 1,221.15 Million in 2019, it is projected to reach US$ 3,062.94 Million by 2027.

What is the CAGR for Europe Neurological Biomarkers Market by (2020 - 2027)?

As per our report Europe Neurological Biomarkers Market, the market size is valued at US$ 1,221.15 Million in 2019, projecting it to reach US$ 3,062.94 Million by 2027. This translates to a CAGR of approximately 12.4% during the forecast period.

What segments are covered in this report?

The Europe Neurological Biomarkers Market report typically cover these key segments-

  • 产品 (蛋白质组学生物标志物, 基因组学生物标志物, 代谢组学生物标志物, 成像生物标志物)
  • 应用 (阿尔茨海默病, 帕金森病, 精神分裂症, 亨廷顿病, 脊髓性肌萎缩症)
  • 最终用户 (制药和生物技术公司, 临床诊断, 研究组织)
  • What is the historic period, base year, and forecast period taken for Europe Neurological Biomarkers Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Neurological Biomarkers Market report:

  • Historic Period : 2017-2018
  • Base Year : 2019
  • Forecast Period : 2020-2027
  • Who are the major players in Europe Neurological Biomarkers Market?

    The Europe Neurological Biomarkers Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Thermo Fisher Scientific, Inc
  • Myriad Genetics
  • QIAGEN
  • Abbott
  • Merck KGaA
  • Who should buy this report?

    The Europe Neurological Biomarkers Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Neurological Biomarkers Market value chain can benefit from the information contained in a comprehensive market report.